These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18690497)

  • 21. Clinical characteristics of patients with late-onset multiple sclerosis.
    Kis B; Rumberg B; Berlit P
    J Neurol; 2008 May; 255(5):697-702. PubMed ID: 18283394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
    Trojano M; Paolicelli D; Fuiani A; Pellegrini F; Iaffaldano P; Direnzo V; D'Onghia M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S225-6. PubMed ID: 18690499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evoked potentials in neurology: a review of techniques and indications.
    Lascano AM; Lalive PH; Hardmeier M; Fuhr P; Seeck M
    J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):688-696. PubMed ID: 28235778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 25. Neurophysiological and cognitive markers of disease evolution in multiple sclerosis.
    Comi G; Martinelli V; Locatelli T; Leocani L; Medaglini S
    Mult Scler; 1998 Jun; 4(3):260-5. PubMed ID: 9762686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of MRI in the diagnosis of multiple sclerosis.
    Traboulsee AL; Li DK
    Adv Neurol; 2006; 98():125-46. PubMed ID: 16400831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuroimaging and functional analyses for multiple sclerosis].
    Kira J
    Rinsho Byori; 2000 Sep; 48(9):814-22. PubMed ID: 11051795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of clinical course.
    Hume AL; Waxman SG
    J Neurol Sci; 1988 Feb; 83(2-3):191-210. PubMed ID: 3128646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of MRS and fMRI in multiple sclerosis.
    Tartaglia MC; Arnold DL
    Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis-modifying therapy in multiple sclerosis.
    Comi G; Colombo B; Martinelli V
    Neurol Sci; 2000; 21(4 Suppl 2):S893-9. PubMed ID: 11205370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The diagnostic value of nuclear magnetic resonance tomography, multimodal evoked potentials and cerebrospinal fluid examination in multiple sclerosis].
    Staffen W; Trinka E; Ladurner G
    Nervenarzt; 1993 Apr; 64(4):226-32. PubMed ID: 8506010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.
    Schlaeger R; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
    Mult Scler; 2014 Sep; 20(10):1348-54. PubMed ID: 24574192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 34. Correlations between clinical and magnetic resonance imaging findings in multiple sclerosis.
    Boné G; Ladurner G; Artmann W; Bsteh C
    Eur Neurol; 1988; 28(4):212-6. PubMed ID: 3416890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnosis of multiple sclerosis.
    Lublin FD
    Curr Opin Neurol; 2002 Jun; 15(3):253-6. PubMed ID: 12045721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
    Rovaris M; Barkhof F; Calabrese M; De Stefano N; Fazekas F; Miller DH; Montalban X; Polman C; Rocca MA; Thompson AJ; Yousry TA; Filippi M
    Neurology; 2009 May; 72(19):1693-701. PubMed ID: 19433744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-beta responders and non-responders. A biological approach.
    Bertolotto A; Gilli F
    Neurol Sci; 2008 Sep; 29 Suppl 2():S216-7. PubMed ID: 18690496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes.
    Pisa M; Croese T; Dalla Costa G; Guerrieri S; Huang SC; Finardi A; Fabbella L; Sangalli F; Colombo B; Moiola L; Martinelli V; Comi G; Furlan R; Leocani L
    Brain; 2021 Apr; 144(3):848-862. PubMed ID: 33829250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis--yes.
    Giovannoni G
    Mult Scler; 2015 Feb; 21(2):134-6. PubMed ID: 25623249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.